JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP) Files An 8-K Entry into a Material Definitive Agreement

Item1.01(a)

On November10, 2016, Juniper Pharmaceuticals, Inc. (the
Company) entered into (i)an amendment to that
certain License Agreement, dated as of March3, 2010, by and among
the Company, as successor to Columbia Laboratories, Inc.,
Coventry Acquisition, Inc. and Watson Pharmaceuticals, Inc.(the
License Agreement Amendment) and (ii)an
amendment to that certain Purchase and Collaboration Agreement,
dated as of March3, 2010, by and among the Company, as successor
to Columbia Laboratories, Inc., Coventry Acquisition, Inc. and
Watson Pharmaceuticals, Inc. (the Purchase and
Collaboration Agreement Amendment, and together with the
License Agreement Amendment, the Amendments). to
the Amendments, the Company, in consideration of its receipt of a
one-time payment of $11,000,000, will no longer be entitled to
receive, effective November1, 2016, royalty payments from
Allergan in connection with the sale of CRINONE in the United
States.

The Company expects to file the Amendments as exhibits to its
Annual Report on Form 10-K for the fiscal year ending December31,
2016. The foregoing descriptions of the Amendments are qualified
in their entirety by reference to the complete text of such
amendments when filed.

On November15, 2016, the Company issued a press release related
to the Amendments. A copy of the press release is furnished and
attached as Exhibit 99.1 hereto and is incorporated herein by
reference. The information being furnished to Item7.01 of this
Current Report on Form 8-K and contained in Exhibit 99.1 shall
not be deemed to be filed for purposes of Section18 of the
Exchange Act of 1934, as amended, or otherwise subject to the
liability of that section, and shall not be incorporated by
reference into any registration statement or other document filed
under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.

(d) Exhibits

About JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP)

Juniper Pharmaceuticals, Inc., formerly Columbia Laboratories, Inc., is a women’s health therapeutic company focused on developing intra-vaginal therapeutics that addresses the medical needs in women’s health. The Company operates through two segments: product and service. The product segment includes supply chain management for CRINONE. The product segment also includes the royalty stream the Company receives from Allergan for CRINONE sales in the United States, as well as the development of new product candidates. The service segment includes pharmaceutical development, clinical trial manufacturing and advanced analytical and consulting services for the its customers, as well as characterizing and developing pharmaceutical product candidates for its internal programs, and managing the preclinical and clinical manufacturing of COL-1077 and its intra-vaginal ring (IVR). Its product and product development programs include CRINONE 8%, COL-1077, JNP-0101, JNP-0101 and JNP-0301.

JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP) Recent Trading Information

JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP) closed its last trading session down -0.30 at 5.65 with – shares trading hands.